More and more life science data is available, from both the chemical and biological domains; however, how to translate data into knowledge – and how to make decisions based on life science data - is much less clear. In our work, we hence employ and develop expertise from the cheminformatics, bioinformatics, and computer-aided drug design fields for a wide variety of purposes: From personalized medicine design e.g. in cancer, to explaining adverse drug reactions, and predicting the potential toxicity of substances that have not even yet been synthesized.
Part of the work in our group is based on methods development, and part is applied research, which we conduct in collaboration with a variety of external partners, both in academia, as well as industrial partners from the chemical and pharmaceutical fields.
This presentation will give an overview of the rather diverse research taking place in our group, whose members come from backgrounds as diverse as chemistry, biology, medicine, computer science, toxicology, as well as many other fields.
RELEVANT PAPPERS
Polypharmacological in Silico Bioactivity Profiling and Experimental Validation Uncovers Sedative-Hypnotic Effects of Approved and Experimental Drugs in Rat ACS Chem. Biol. 2017, 12, 1593.
Cheminformatics Research at the Unilever Centre for Molecular Science Informatics Cambridge Molecular Informatics 2015, 34, 626.
E ab454@cam.ac.uk
T 01223 762983
W www.ch.cam.ac.uk/group/bender/